Publicacións en colaboración con investigadores/as de University of Glasgow (67)

2024

  1. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European male ageing study

    Reviews in Endocrine and Metabolic Disorders

  2. The relationship between low prolactin and type 2 diabetes

    Reviews in Endocrine and Metabolic Disorders

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. Reproductive hormone levels, androgen receptor CAG repeat length and their longitudinal relationships with decline in cognitive subdomains in men: The European Male Ageing Study.

    Physiology and Behavior, Vol. 252

2021

  1. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227

2019

  1. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    The Lancet, Vol. 393, Núm. 10184, pp. 1937-1947

2018

  1. Elevated luteinizing hormone despite normal testosterone levels in older men—natural history, risk factors and clinical features

    Clinical Endocrinology, Vol. 88, Núm. 3, pp. 479-490

  2. Reproductive hormone levels predict changes in frailty status in community-dwelling older men: European male ageing study prospective data

    Journal of Clinical Endocrinology and Metabolism, Vol. 103, Núm. 2, pp. 701-709

  3. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS

    Clinical Endocrinology, Vol. 89, Núm. 4, pp. 459-469

2017

  1. Changes in prevalence of obesity and high waist circumference over four years across European regions: the European male ageing study (EMAS)

    Endocrine, Vol. 55, Núm. 2, pp. 456-469

  2. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 377, Núm. 13, pp. 1228-1239

  3. Evaluation of cognitive subdomains, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in the European Male Ageing Study

    European Journal of Nutrition, Vol. 56, Núm. 6, pp. 2093-2103

  4. Frailty and bone health in European men

    Age and Ageing, Vol. 46, Núm. 4, pp. 635-641

  5. Glycemia but not the Metabolic Syndrome is Associated with Cognitive Decline: Findings from the European Male Ageing Study

    American Journal of Geriatric Psychiatry, Vol. 25, Núm. 6, pp. 662-671

  6. Nonandrogenic anabolic hormones predict risk of frailty: European male ageing study prospective data

    Journal of Clinical Endocrinology and Metabolism, Vol. 102, Núm. 8, pp. 2798-2806

2016

  1. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone

    Journal of Clinical Endocrinology and Metabolism, Vol. 101, Núm. 7, pp. 2647-2657

  2. Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study

    Osteoporosis International, Vol. 27, Núm. 11, pp. 3227-3237

  3. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: Longitudinal Data from the European Male Ageing Study

    Clinical Endocrinology, Vol. 85, Núm. 6, pp. 891-901

  4. The androgen receptor gene CAG repeat in relation to 4-year changes in androgen-sensitive endpoints in community-dwelling older European men

    European Journal of Endocrinology, Vol. 175, Núm. 6, pp. 583-593

2015

  1. Associations between sex steroids and the development of metabolic syndrome: A longitudinal study in European men

    Journal of Clinical Endocrinology and Metabolism, Vol. 100, Núm. 4, pp. 1396-1404